Madeleine Duvic

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Photopheresis versus transimmunization?
    Madeleine Duvic
    MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030, USA
    Leuk Lymphoma 47:1449. 2006
  2. ncbi Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study
    Niyati Mukherjee
    Department of Internal Medicine, University of North Carolina Hospitals, Chapel Hill, USA
    BMC Dermatol 9:11. 2009
  3. ncbi Optimizing denileukin diftitox (Ontak) therapy
    Madeleine Duvic
    The University of Texas MD Anderson Cancer Center, Division of Internal Medicine, Department of Dermatology, 1515 Holcombe Blvd, Unit 1452, Houston, TX 77030, USA
    Future Oncol 4:457-69. 2008
  4. ncbi CD30+ Neoplasms of the Skin
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA
    Curr Hematol Malig Rep 6:245-50. 2011
  5. ncbi Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
    Madeleine Duvic
    Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 434, Houston, TX 77030 4409, USA
    Blood 109:31-9. 2007
  6. ncbi Mycosis fungoides: pathophysiology and emerging therapies
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:S21-8. 2007
  7. ncbi Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 121:902-9. 2003
  8. ncbi Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)
    Madeleine Duvic
    Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 2:222-8. 2002
  9. ncbi Alopecia areata registry: an overview
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Investig Dermatol Symp Proc 8:219-21. 2003
  10. ncbi Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    J Cutan Med Surg 7:3-7. 2003

Research Grants

  1. CUTANEOUS ONCOLOGY
    Madeleine Duvic; Fiscal Year: 2004

Detail Information

Publications122 found, 100 shown here

  1. ncbi Photopheresis versus transimmunization?
    Madeleine Duvic
    MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030, USA
    Leuk Lymphoma 47:1449. 2006
  2. ncbi Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study
    Niyati Mukherjee
    Department of Internal Medicine, University of North Carolina Hospitals, Chapel Hill, USA
    BMC Dermatol 9:11. 2009
    ..The objective of this study was to examine the current practices of southeastern United States dermatologists for the treatment of AA...
  3. ncbi Optimizing denileukin diftitox (Ontak) therapy
    Madeleine Duvic
    The University of Texas MD Anderson Cancer Center, Division of Internal Medicine, Department of Dermatology, 1515 Holcombe Blvd, Unit 1452, Houston, TX 77030, USA
    Future Oncol 4:457-69. 2008
    ....
  4. ncbi CD30+ Neoplasms of the Skin
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA
    Curr Hematol Malig Rep 6:245-50. 2011
    ..The development of targeted therapy for CD30+ CTCLs will help in understanding the importance of the CD30 death receptor in pathogenesis and will improve treatment options...
  5. ncbi Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
    Madeleine Duvic
    Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 434, Houston, TX 77030 4409, USA
    Blood 109:31-9. 2007
    ..Vorinostat demonstrated activity in heavily pretreated patients with CTCL. The 400 mg daily regimen had the most favorable safety profile and is being further evaluated...
  6. ncbi Mycosis fungoides: pathophysiology and emerging therapies
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:S21-8. 2007
    ..The emergence of novel targeted therapies such as biologic agents, histone deacetylase inhibitors, and purine nucleoside phosphorylase inhibitors offers promise for more effective and safer treatment strategies for refractory CTCLs...
  7. ncbi Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 121:902-9. 2003
    ..This association suggests that reversal of TIG-3 expression may help to explain the mechanism of retinoid action in epidermal differentiation and chemoprevention...
  8. ncbi Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)
    Madeleine Duvic
    Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 2:222-8. 2002
    ..Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity...
  9. ncbi Alopecia areata registry: an overview
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Investig Dermatol Symp Proc 8:219-21. 2003
    ..org. Samples of DNA, lymphoblast lines, and sera, as well as epidemiology and quality-of-life data, are being collected from well-characterized individuals, multiplex families, and sib pairs for future research studies and investigators...
  10. ncbi Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    J Cutan Med Surg 7:3-7. 2003
  11. ncbi Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity
    M Duvic
    Section of Dermatology, Division of Internal Medicine Specialties, M D Anderson Cancer Center, Houston, TX 77005, USA
    Clin Lymphoma 1:141-5. 2000
    ..Enterococcal infections in CTCL tumors may be recognized as a distinct clinical entity requiring specific intervention...
  12. ncbi Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective
    M Duvic
    Dermatology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 1:S15-20. 2000
    ..New agents including bexarotene (a rexinoid) and DAB(389)IL-2 (interleukin-2 diphtheria fusion protein) offer new therapeutic options that are advantageous for treatment of mycosis fungoides in later stages...
  13. ncbi Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms
    M Duvic
    Dermatology Section, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 1:S51-5. 2000
    ..With three new highly effective agents in the armamentarium for the treatment of CTCL, new combination treatment algorithms can be tested to achieve maximal benefit and quality of life for these patients...
  14. ncbi A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
    J Am Acad Dermatol 55:807-13. 2006
    ..Progression of mycosis fungoides is associated with Th(2) cytokines produced by a clonal proliferation of epidermotropic T-helper cells...
  15. ncbi Vorinostat in cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Drugs Today (Barc) 43:585-99. 2007
    ..Vorinostat, in combination with other agents such as radiation therapy and chemotherapy, can have synergistic or additive effects in a variety of cancers in clinical trials...
  16. ncbi Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies
    Madeleine Duvic
    Department of Dermatology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:33-40. 2007
    ..These drugs, in combination with currently used therapies, may increase the number and combinations of therapies available for the treatment of this chronic condition to optimize long-lasting responses in CTCL...
  17. ncbi Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
    Madeleine Duvic
    University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030, USA
    Expert Opin Investig Drugs 16:1111-20. 2007
    ..The common side effects of vorinostat, which are similar in all studies, include gastrointestinal symptoms, fatigue and thrombocytopenia and the most common serious event was thrombosis...
  18. ncbi Cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 51:S43-5. 2004
  19. ncbi Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Clin Lymphoma Myeloma 7:51-8. 2006
    ..The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL)...
  20. ncbi Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome
    Madeleine Duvic
    Department of Dermatology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Oncol 28:2365-72. 2010
    ..We studied the safety and efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL)...
  21. ncbi Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Box 1492, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:412-6. 2009
    ....
  22. ncbi Emerging new therapies for cutaneous T-cell lymphoma
    M Duvic
    Department of Dermatology, M D Anderson Cancer Center, Houston, Texas, USA
    Dermatol Clin 18:147-56. 2000
    ..In summary, the treatment of CTCL should continue to improve and should be focused on strategies that preserve the immune function in these patients...
  23. ncbi Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer
    M Duvic
    Department of Internal Medical Specialties, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 6:3249-59. 2000
    ..012). TIG-3 mRNA was significantly higher in normal control skin (P = 0.001), in paired adjacent skin (median, 3; P = 0.007), and in overlying epidermis (median, 3.0; P = 0.0001) than in 21 SCC specimens as a group (median, 1.5)...
  24. ncbi Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials
    M Duvic
    Section of Dermatology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Dermatol 136:1461-9. 2000
    ..To evaluate the efficacy and safety of topical alitretinoin gel (9-cis-retinoic acid [LGD1057], Panretin gel; Ligand Pharmaceuticals, Inc, San Diego, Calif) in cutaneous Kaposi sarcoma (KS)...
  25. ncbi Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 122:2077-84. 2008
    ..013) in modifying risk. Together, these findings suggest that VDR polymorphisms may directly affect or modify the risk associated with known melanoma risk factors. Larger, population-based studies are needed to replicate our findings...
  26. ncbi Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:6532-9. 2007
    ..To examine the role of suboptimal DNA repair capacity (DRC) for UV light-induced DNA damage in the development of nonmelanoma skin cancer (NMSC) and tumor progression...
  27. ncbi Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 127:276-80. 2007
    ..26; 95% CI, 1.00-1.59) genotypes, compared with the VDR-FokI FF genotype. In conclusion, genetic variants (i.e., TaqI t protective allele and FokI f risk allele) in VDR may alter risk of CM...
  28. ncbi Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Pharmacogenet Genomics 16:253-63. 2006
    ..In conclusion, genetic variants in the FAS and FASLG genes may contribute to the etiology of CMM in the general population, particularly in those with a low risk of sunlight-induced CMM...
  29. ncbi Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Unit 1365, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 15:2526-32. 2006
    ..We concluded that genetic variants of the XPD gene might serve as biomarkers for susceptibility to cutaneous melanoma...
  30. ncbi Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma
    Chunying Li
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Hum Mutat 29:1443-51. 2008
    ..Therefore, these CASP8 and CASP10 polymorphisms may be biomarkers for susceptibility to CM...
  31. ncbi In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis
    Li-E Wang
    Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 97:1822-31. 2005
    ..CONCLUSIONS: UVB-induced mutagen sensitivity may play a role in susceptibility to NMSC but not to CMM...
  32. ncbi Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies
    Apostolia-Maria Tsimberidou
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:574-80. 2004
    ..CONCLUSIONS: IFN-alpha and isotretinoin combination therapy had antitumor activity and was well tolerated in heavily pretreated patients with lymphoid malignancies...
  33. ncbi Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study
    Narin Apisarnthanarax
    Department of Dermatology, University of Texas M. D. Anderson Cancer Center, Houston 77030-4095, USA
    J Am Acad Dermatol 50:600-7. 2004
    ..CONCLUSION: In this small pilot study, tazarotene 0.1% gel was a well-tolerated and effective adjuvant topical for the treatment of refractory MF lesions by clinical and histologic assessments...
  34. ncbi Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 27:1894-901. 2006
    ..Larger studies with more SNPs in the BER genes are needed to verify these findings...
  35. ncbi Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1570-8. 2007
    ..The authors hypothesized that selected functional single-nucleotide polymorphisms (SNPs) in the nNOS and iNOS genes are associated with the risk of CM...
  36. ncbi CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma
    Rakhshandra Talpur
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4095, USA
    J Invest Dermatol 126:575-83. 2006
    ..These data suggest that high CD25 expression by IHC is associated with advanced CTCL and with clinical response to denileukin diftitox therapy...
  37. ncbi CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate
    Justin J Leitenberger
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Am Acad Dermatol 58:480-4. 2008
    ..Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias...
  38. ncbi 4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of nonmelanoma skin cancer: a case-control analysis
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 127:196-205. 2007
    ..However, there is a lack of correlation between UVB-induced b/c and 4-NQO-induced b/c in this study population. Therefore, these findings need to be verified by additional studies...
  39. ncbi Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
    Lynn Petukhova
    Department of Dermatology, Columbia University, New York, New York 10032, USA
    Nature 466:113-7. 2010
    ..We have defined the genetic underpinnings of AA, placing it within the context of shared pathways among autoimmune diseases, and implicating a novel disease mechanism, the upregulation of ULBP ligands, in triggering autoimmunity...
  40. ncbi Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome
    Jonathan L Curry
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Cutan Pathol 38:295-7. 2011
    ..As far as we are aware, this is the first report of an Epstein-Barr virus-associated B-cell lymphoproliferative disorder, secondary to methotrexate therapy in a patient with mycosis fungoides/Sézary syndrome...
  41. ncbi p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma
    Hongbing Shen
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 121:1510-4. 2003
    ..Further larger studies are needed to substantiate our findings...
  42. ncbi Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene
    Rakhshandra Talpur
    Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, 77030-4095, USA
    Clin Lymphoma Myeloma 6:488-92. 2006
    ..The purpose of this case report is to show the value of sequential combination therapy for improving overall response...
  43. ncbi Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling
    Chunlei Zhang
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 130:2110-9. 2010
    ..Our findings provide a mechanistic rationale for the potential use of curcumin as a therapeutic agent for patients with CTCL...
  44. ncbi Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma
    Qingyi Wei
    Department of Epidemiology, Unit 189, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Natl Cancer Inst 95:308-15. 2003
    ....
  45. ncbi The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells
    Chunlei Zhang
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 123:380-7. 2004
    ..Our findings suggest the rationale for further investigation of the clinical potential of CDDO, either alone or in combination with bexarotene for MF/SS patients...
  46. ncbi Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Eur J Cancer 47:107-15. 2011
    ..56 and 2.13, 95% CIs=1.02-2.38 and 1.22-3.70, respectively). These findings suggest that MMP1 promoter polymorphisms may individually or jointly play roles in the development of CM...
  47. ncbi The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome
    Ming Yang Bi
    Baylor College of Medicine, Houston, Texas, USA
    J Am Acad Dermatol 64:53-63. 2011
    ..Alopecia can be a manifestation of mycosis fungoides (MF) and Sézary syndrome (SS), but the prevalence is unknown...
  48. ncbi Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma
    Chunlei Zhang
    Department of Dermatology, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Dermatol Ther 16:322-30. 2003
    ..Identification of new receptor subtype-selective retinoids, combination of various receptor-selective retinoids or other agents, and a new drug delivery system may improve the clinical efficacy of retinoids in the future...
  49. ncbi Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients
    Steve A May
    Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Am J Dermatopathol 29:62-7. 2007
    ..These cases are strikingly similar, and may represent an unusual clinicopathologic type of T-cell lymphoma that can hone to cutaneous and oral mucosal sites with a slowly progressive natural history...
  50. ncbi Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
    Christiane Querfeld
    Department of Dermatology, Northwestern University, Chicago, IL 60611, USA
    Leuk Lymphoma 52:1474-80. 2011
    ..Enzastaurin was well tolerated with mostly grade 1-2 adverse events, mainly diarrhea and fatigue. There were two adverse event-related drug discontinuations with one possibly treatment-related...
  51. ncbi Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells
    Chunlei Zhang
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 128:2728-35. 2008
    ..Our findings underlie the therapeutic potential of avicin D in patients with SS...
  52. ncbi Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides
    Putao Cen
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 58:382-6. 2008
    ..29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer...
  53. ncbi Clusterin expression correlates with stage and presence of large cells in mycosis fungoides
    Pranil Chandra
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 85, Houston, TX 77030, USA
    Am J Clin Pathol 131:511-5. 2009
    ..Clusterin expression was not specific for MF as it also was positive in 3 of 3 cases of LyP, 2 of 2 systemic ALCL cases involving skin, 7 of 16 cutaneous ALCLs, and 1 of 6 PTCLs...
  54. ncbi Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)
    Rakhshandra Talpur
    Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA
    Leuk Lymphoma 43:121-6. 2002
    ....
  55. ncbi Optimizing bexarotene therapy for cutaneous T-cell lymphoma
    Rakhshandra Talpur
    Division of Internal Medicine, Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 47:672-84. 2002
    ..When bexarotene is combined with other active CTCL therapies, higher RRs were achieved in patients with advanced disease, without unacceptable side effects...
  56. ncbi Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy
    Dan Jones
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5587-94. 2004
    ..Using concurrent tumor samples from different anatomical sites, we compared expression of the therapeutic targets CD25 and CD30 in T-cell lymphoma (TCL)...
  57. ncbi Efficacy and safety of topical tazarotene: a review
    Rakhashandra Talpur
    University of Texas, MD Anderson Cancer Center, Department of Dermatology, Houston, Texas, USA
    Expert Opin Drug Metab Toxicol 5:195-210. 2009
    ..Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris...
  58. ncbi History of atopy or autoimmunity increases risk of alopecia areata
    Nazila Barahmani
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 61:581-91. 2009
    ..The association between a history of atopy or autoimmune diseases and risk of alopecia areata (AA) is not well established...
  59. ncbi Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series
    Kelley A Vidulich
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77027, USA
    Int J Dermatol 48:598-602. 2009
    ..Mycosis fungoides (MF)/Sézary syndrome (SS) patients are immunocompromised and thus may be susceptible to high-risk human papillomavirus (HPV) infections that are difficult to treat...
  60. ncbi Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides
    Grace Sun
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Am Acad Dermatol 60:231-5. 2009
    ..Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, is most often seen in middle-aged to elderly men...
  61. ncbi Skin directed therapy for mycosis fungoides: a review
    Cindy Berthelot
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Drugs Dermatol 7:655-66. 2008
    ....
  62. ncbi Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma
    Madeleine Duvic
    Division of Internal Medicine, Department of Dermatology, University of Texas M. D. Anderson Cancer Center, Houston 77030-4095, USA
    J Am Acad Dermatol 49:35-49. 2003
    ....
  63. ncbi Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action
    Chunlei Zhang
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 125:1045-52. 2005
    ..Our data suggest that selective induction of malignant T cell apoptosis and modulation of acetylated histones, p21(WAF1), bax, Stat6, and caspase-3 may underlie the therapeutic action of SAHA in CTCL patients...
  64. ncbi High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma
    Sean D Doherty
    Baylor College of Medicine, Houston, Texas, USA
    Melanoma Res 16:461-3. 2006
  65. ncbi Treatment of cutaneous T cell lymphoma: current status and future directions
    Narin Apisarnthanarax
    Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Clin Dermatol 3:193-215. 2002
    ..Further developments for CTCL may include more selective immunomodulatory agents, vaccines, and monoclonal antibodies...
  66. ncbi Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas
    Apostolia-Maria Tsimberidou
    Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 51:200-4. 2004
    ..CONCLUSION: This pilot study suggests that etanercept is safe and generally well tolerated in patients with CTCL. The effect of etanercept in a larger cohort of patients with early disease merits investigation...
  67. ncbi Clonal heterogeneity in mycosis fungoides and its relationship to clinical course
    Francisco Vega
    Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 100:3369-73. 2002
    ..Demonstration of identical clonal GRs in multiple biopsy specimens at the time of diagnosis may provide prognostic information related to disease progression...
  68. ncbi Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides
    Farah Ghori
    Department of Dermatology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 91:2205-8. 2006
    ..CONCLUSIONS: Monitoring thyroid function before and during treatment with denileukin diftitox is recommended. Symptomatic thyrotoxicosis may be missed due to other acute reactions to the drug, and subsequent hypothyroidism may develop...
  69. ncbi Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1
    Parul Hazarika
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 64:7361-9. 2004
    ..Flot-2 binds to PAR-1, a known upstream mediator of major signal transduction pathways implicated in cell growth and metastasis, and may thereby influence tumor progression...
  70. ncbi Cutaneous T-cell lymphoma. New immunomodulators
    N Apisarnthanarax
    Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Dermatol Clin 19:737-48. 2001
    ..It seems that further delineation of CTCL cytokine profile changes and immunologic aberrations are key in developing effective immunomodulators that are able to reverse these alterations...
  71. ncbi DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma
    Zhigang Duan
    Departments of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 11:1142-3. 2002
  72. ncbi Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas
    Di Lu
    Department of Hematopathology, UT-M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Cutan Pathol 29:465-72. 2002
    ....
  73. ncbi Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox
    Kelley Vidulich
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 8:55-8. 2008
    ..We describe a patient with deep ulcers initially diagnosed as pyoderma gangrenosum, which was reclassified as CGD-TCL. Local radiation followed by weekly infusions of denileukin diftitox put the patient into remission...
  74. ncbi Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series
    Apostolia-Maria Tsimberidou
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 100:342-9. 2004
    ..A transient early "flare" of disease was observed in some responders. CONCLUSIONS: At these doses, pentostatin was reasonably well tolerated and is an effective drug for the treatment of T-cell lymphomas...
  75. ncbi Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy
    Cindy Berthelot
    University of Texas Medical School Southwestern, Dallas, 77030, USA
    Clin Lymphoma Myeloma 6:329-32. 2006
    ..Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab. The mechanisms and occurrence of lymphoma after immune response modifiers are discussed...
  76. ncbi Current treatment of Cutaneous T-Cell Lymphoma
    M Duvic
    University of Texas, MD Anderson Cancer Center, USA
    Dermatol Online J 7:3. 2001
    ..In the United States, the incidence of these diseases is rising faster than any other cancer. Environmental triggers may be important in the evolution of malignancy. Current therapy is reviewed with emphasis on a new retinoid, Targretin...
  77. ncbi Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  78. ncbi Mortality risk from squamous cell skin cancer
    Gary L Clayman
    Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:759-65. 2005
    ..To identify nonmelanoma skin cancer patients with squamous cell carcinoma (SCC) who are at greatest risk of disease-specific mortality...
  79. ncbi Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel
    Ashley G Perna
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Clin Lymphoma 5:190-3. 2004
    ..However, the LyP relapsed and proved refractory to psoralen plus ultraviolet-A phototherapy, and was only temporarily and partially responsive to bexarotene and denileukin diftitox...
  80. ncbi Coexistent psoriasis and lupus erythematosus treated with alefacept
    Cindy Berthelot
    Department of Internal Medicine, University of Texas Houston Health Science Center, Houston, TX, USA
    Am J Clin Dermatol 8:47-50. 2007
    ..The patient's arthritis flared after the second infusion of infliximab, which was discontinued. During treatment with alefacept, the patient's psoriasis improved markedly without exacerbation of his photosensitive SCLE lesions...
  81. ncbi The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force
    Timothy G Berger
    Department of Dermatology, University of California, San Francisco, California, USA
    J Am Acad Dermatol 54:818-23. 2006
  82. ncbi Multiple plaques on the hands and feet. Mycosis fungoides (MF) palmaris et plantaris (MFPP)
    Thomas J Lambert
    Texas Tech University School of Medicine, Lubbock, TX, USA
    Arch Dermatol 143:109-14. 2007
  83. ncbi Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis
    Jenny Vu
    Department of Dermatology, University of Texas MD Anderson Cancer Center and Medical School, Houston, Texas 77030 4009, USA
    Am J Clin Dermatol 8:307-10. 2007
    ..Our case is the second reported case of common variable immunodeficiency syndrome associated with EV...
  84. ncbi Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma
    Kristel Polder
    Memorial Hermann Hospital, University of Texas Health Science Center at Houston, TX, USA
    Leuk Lymphoma 46:1807-11. 2005
    ..The clinical features and pathology were compatible with toxic epidermal necrolysis. This is the first reported case of toxic epidermal necrolysis in the literature associated with denileukin diftitox...
  85. ncbi Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome
    Daniel J Lenihan
    Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, USA
    Blood 104:655-8. 2004
    ..The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation...
  86. ncbi Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA
    Xiao Ni
    Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 128:2631-9. 2008
    ..These data support the concept of using tumor mRNA for a vaccine strategy that requires small amounts of tumor cells without need for specific antigens in patients with SzS...
  87. ncbi Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome
    R Talpur
    Division of Internal Medicine, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Dermatol 159:105-12. 2008
    ..Superantigens from Staphylococcus aureus can stimulate T cells...
  88. ncbi Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy
    N Barahmani
    Department of Dermatology, University of Texas M D Anderson Center, Houston, TX 77030, USA
    Clin Exp Dermatol 35:409-16. 2010
    ..The role of T helper (Th)1 and Th2 cytokines in the pathogenesis of AA have not been established...
  89. ncbi Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy
    A H Sarris
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:398-405. 2001
    ..Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin's lymphoma (PCNHL)...
  90. ncbi Dendritic cells and cutaneous T-cell lymphomas
    X Ni
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    G Ital Dermatol Venereol 146:103-13. 2011
    ..Further understanding of DCs and their role in CTCLs can help us to uncover the pathogenesis of this disease and to further explore the therapeutic uses of DCs...
  91. ncbi Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma
    M Duvic
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Arch Dermatol 137:581-93. 2001
    ..To determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif)...
  92. ncbi Central hypothyroidism associated with retinoid X receptor-selective ligands
    S I Sherman
    Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 340:1075-9. 1999
    ....
  93. ncbi Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment
    J A Pielop
    Baylor College of Medicine, Houston, Texas, USA
    Int J Dermatol 40:505-11. 2001
    ....
  94. ncbi Molecular mechanisms of tazarotene action in psoriasis
    M Duvic
    Department of Dermatology, University of Texas Medical School, Houston 77030, USA
    J Am Acad Dermatol 37:S18-24. 1997
    ..The effect of tazarotene on these markers is probably a direct effect on gene expression rather than an indirect effect associated with disease improvement...
  95. ncbi Therapy options in cutaneous T-cell lymphoma
    N Apisarnthanarax
    Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, TX 77030-4095, USA
    Expert Rev Anticancer Ther 1:403-20. 2001
    ..This article will present and discuss the optimal therapeutic agents for all clinical stages of CTCL patients, based on currently available and investigational agents...
  96. ncbi Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results
    M Duvic
    M.D. Anderson Cancer Center, Houston, TX
    J Clin Oncol 19:2456-71. 2001
    ..Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL...
  97. ncbi HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma
    C M Jackow
    Department of Dermatology, University of Texas Medical School, Houston 77030, USA
    J Invest Dermatol 107:373-6. 1996
    ..These data suggest that certain HLA-DRB and DQB1 alleles, also associated with other T-cell-mediated skin diseases, may participate in the pathogenesis of or susceptibility to CTCL...
  98. ncbi Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor V beta expansion, and Staphylococcus aureus: when does follicular mucinosis become mycosis fungoides?
    C M Jackow
    Department of Dermatology, University of Texas Medical School, Houston 77030, USA
    J Am Acad Dermatol 37:828-31. 1997
    ..Epidermotropic T-cell skin diseases with oligoclonal T-cell proliferations may be the result of HLA- and cytokine-determined reaction patterns to persistent antigens...
  99. ncbi Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
    X Ni
    Department of Dermatology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 7:2682-92. 2001
    ..01 +/- 0.86%) compared with non-FasL expressing areas (13.53 +/- 3.54%; P < 0.02). These results suggest that a potential mechanism of tumor immune escape in MF is FasL-mediated apoptosis of infiltrating CD8+ CTLs...
  100. ncbi Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood
    D Jones
    Division of Pathology and Laboratory Medicine, University of Texas-M.D. Anderson Cancer Center, Houston, USA
    Am J Clin Pathol 115:885-92. 2001
    ....
  101. ncbi Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with filopodia formation
    P Hazarika
    Department of Dermatology, University of Texas Medical School and Department of Medical Specialties, Section of Dermatology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Cell Biochem 75:147-59. 1999
    ..Thus, the function of flotillin 2 may resemble that of the goldfish optic nerve neuronal regeneration proteins, Reggie 1 and 2...

Research Grants1

  1. CUTANEOUS ONCOLOGY
    Madeleine Duvic; Fiscal Year: 2004
    This is a mid-career development award application for Madeleine Duvic, Professor of Medicine and Chief of Dermatology at the MD Anderson Cancer Center...